VAXNEUVANCE

Medicine identity

Source reference

101153

DIN

02522403

Form

Suspension

Company as listed by source

MERCK CANADA INC

Source status

Marketed (2022-09-02)

Source last updated

2026-08-18

Source-listed ingredients

• PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 1 — 2 MCG — per 0.5 ML
• PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 3 — 2 MCG — per 0.5 ML
• PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 4 — 2 MCG — per 0.5 ML
• PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 5 — 2 MCG — per 0.5 ML
• PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 6A — 2 MCG — per 0.5 ML
• PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 6B — 4 MCG — per 0.5 ML
• PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 7F — 2 MCG — per 0.5 ML
• PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 9V — 2 MCG — per 0.5 ML
• PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 14 — 2 MCG — per 0.5 ML
• PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 18C — 2 MCG — per 0.5 ML
• PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 19A — 2 MCG — per 0.5 ML
• PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 19F — 2 MCG — per 0.5 ML
• PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 22F — 2 MCG — per 0.5 ML
• PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 23F — 2 MCG — per 0.5 ML
• PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 33F — 2 MCG — per 0.5 ML
• CORYNEBACTERIUM DIPHTHERIAE CRM-197 PROTEIN — 30 MCG — per 0.5 ML

These values do not establish equivalence or a dose recommendation.

Packages

Package details are not available in this snapshot.

Source and coverage

Open Health Canada Drug Product Database →

Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.

Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.